13F Holdings
中文EN

CYRX Cryoport, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1124524 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY11.8%
TTM net income YoY-157.9%
TTM EPS YoY-178.6%
Revenue 3-yr CAGR-6.6%
Net income 3-yr CAGR—

Margins

Gross margin46.9%
Operating margin-20.0%
Net margin-21.5%
FCF margin-9.8%
EBITDA margin-6.6%

Returns

ROE-8.3%
ROA-5.4%
ROIC (approx.)-13.2%
Asset turnover0.25x

Leverage & solvency

Liabilities / assets35.6%
Debt / equity0.00x
Current ratio2.04x
Interest coverage-18.32x

Cash quality & payout

Operating cash flow / net income-0.27x
Accruals ratio-6.9%
Payout ratio—
Capex / revenue15.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20202021-12-31
Income statement
Revenue$176.18M$156.77M$168.66M$237.28M$222.61M
Cost of revenue$93.12M$87.11M$93.33M$133.40M$126.03M
Gross profit$83.05M$69.66M$75.33M$103.87M$96.58M
R&D expense$17.04M$17.71M$18.04M$15.72M$16.84M
SG&A expense$102.82M$109.81M$108.26M$120.06M$97.56M
Operating income-$36.81M-$121.67M-$100.54M-$31.90M-$17.83M
Interest expense$2.36M$3.98M$5.58M$6.14M$4.69M
Pretax income-$32.17M-$104.35M-$84.21M-$35.09M-$273.84M
Income tax$1.80M$359,000$345,000$2.24M$1.69M
Net income$78.30M-$114.76M-$99.59M-$37.33M-$275.53M
EBITDA-$9.09M-$90.91M-$73.05M-$9.14M$2.42M
EPS (basic)1.40-2.49-2.21-0.93-6.18
EPS (diluted)1.40-2.49-2.21-0.93-6.18
Weighted avg. shares (diluted)50.07M49.35M48.74M48.99M45.93M
Banking
Provision for credit losses——$822,000$234,000$26,000
Balance sheet
Cash & equivalents$250.49M$34.14M$35.19M$29.23M$139.10M
Short-term investments$160.71M$216.46M$410.41M$486.73M$489.70M
Receivables$33.36M$25.30M$42.07M$43.86M$39.41M
Inventory$23.19M$21.48M$26.21M$27.68M$16.50M
Current assets$476.17M$341.57M$535.11M$604.18M$693.52M
PP&E, net$85.45M$80.01M$84.86M$63.60M$49.03M
Goodwill$22.40M$20.57M$76.39M$151.12M$146.95M
Intangibles$138.08M$147.93M$194.38M$191.01M$201.43M
Total assets$764.99M$703.49M$957.74M$1.04B$1.11B
Current liabilities$219.02M$64.56M$45.61M$40.85M$42.65M
Total liabilities$262.35M$301.59M$468.72M$482.91M$471.14M
Shareholders' equity$502.64M$401.90M$489.02M$555.84M$641.83M
Shares outstanding49.85M49.91M48.97M48.33M49.62M
Cash flow statement
Operating cash flow-$8.58M-$16.32M-$757,000-$1.85M$8.13M
Capital expenditure$16.44M$17.25M$38.78M$22.11M$23.88M
Free cash flow-$25.02M-$33.58M-$39.54M-$23.96M-$15.76M
Investing cash flow$250.32M$176.81M$36.05M-$59.68M-$469.25M
Financing cash flow-$21.07M-$161.53M-$23.80M-$39.17M$564.34M
Depreciation & amortization$27.71M$30.76M$27.49M$22.77M$20.25M
Stock-based compensation$10.07M$16.57M$19.82M$20.08M$15.35M
Share buybacks$10.01M——$37.96M$0

Free plan shows the latest 5 periods; Pro shows all 16 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.